Multiple Myeloma-Derived Exosomes Regulate the Functions of Mesenchymal Stem Cells Partially Via Modulating MiR-21 and MiR-146a

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2018 Jan 16

PMID 29333170

Citations 40

Authors

Qian Cheng

Xin Li

Jingru Liu

Qinmao Ye

Yanfang Chen

Sanqin Tan

Jing Liu

Affiliations

Soon will be listed here.

Abstract

Exosomes derived from cancer cells can affect various functions of mesenchymal stem cells (MSCs) via conveying microRNAs (miRs). miR-21 and miR-146a have been demonstrated to regulate MSC proliferation and transformation. Interleukin-6 (IL-6) secreted from transformed MSCs in turn favors the survival of multiple myeloma (MM) cells. However, the effects of MM exosomes on MSC functions remain largely unclear. In this study, we investigated the effects of OPM2 (a MM cell line) exosomes (OPM2-exo) on regulating the proliferation, cancer-associated fibroblast (CAF) transformation, and IL-6 secretion of MSCs and determined the role of miR-21 and miR-146a in these effects. We found that OPM2-exo harbored high levels of miR-21 and miR-146a and that OPM2-exo coculture significantly increased MSC proliferation with upregulation of miR-21 and miR-146a. Moreover, OPM2-exo induced CAF transformation of MSCs, which was evidenced by increased fibroblast-activated protein (FAP), -smooth muscle actin (-SMA), and stromal-derived factor 1 (SDF-1) expressions and IL-6 secretion. Inhibition of miR-21 or miR-146a reduced these effects of OPM2-exo on MSCs. In conclusion, MM could promote the proliferation, CAF transformation, and IL-6 secretion of MSCs partially through regulating miR21 and miR146a.

Citing Articles

Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects.

Horenstein A, Faini A, Morandi F, Ortolan E, Storti P, Giuliani N Front Immunol. 2025; 16:1519300.

PMID: 40013150 PMC: 11860881. DOI: 10.3389/fimmu.2025.1519300.

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

Therapeutically Harnessing Tumor Cell-Derived Extracellular Vesicles for Multiple Myeloma: Recent Advances and Future Perspectives.

Xiao S, Chen L, Chen Z, Li Q Pharmaceutics. 2024; 16(11).

PMID: 39598562 PMC: 11597712. DOI: 10.3390/pharmaceutics16111439.

Canine mesenchymal stem cell-derived exosomes attenuate renal ischemia-reperfusion injury through miR-146a-regulated macrophage polarization.

Liu H, Deng H, Huang H, Cao J, Wang X, Zhou Z Front Vet Sci. 2024; 11:1456855.

PMID: 39315083 PMC: 11417097. DOI: 10.3389/fvets.2024.1456855.

Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.

Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L Front Oncol. 2024; 14:1413494.

PMID: 39087026 PMC: 11288838. DOI: 10.3389/fonc.2024.1413494.

References

Roccaro A, Sacco A, Maiso P, Azab A, Tai Y, Reagan M . BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013; 123(4):1542-55. PMC: 3613927. DOI: 10.1172/JCI66517. View

Frassanito M, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A . Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies. Leukemia. 2013; 28(4):904-16. DOI: 10.1038/leu.2013.254. View

Wu T, Liu Y, Fan Z, Xu J, Jin L, Gao Z . miR-21 Modulates the Immunoregulatory Function of Bone Marrow Mesenchymal Stem Cells Through the PTEN/Akt/TGF-β1 Pathway. Stem Cells. 2015; 33(11):3281-90. DOI: 10.1002/stem.2081. View

Li Q, Zhang D, Wang Y, Sun P, Hou X, Larner J . MiR-21/Smad 7 signaling determines TGF-β1-induced CAF formation. Sci Rep. 2013; 3:2038. PMC: 3687228. DOI: 10.1038/srep02038. View

Wang J, Hendrix A, Hernot S, Lemaire M, de Bruyne E, Van Valckenborgh E . Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014; 124(4):555-66. DOI: 10.1182/blood-2014-03-562439. View

Reagan M, Ghobrial I . Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2011; 18(2):342-9. PMC: 3261316. DOI: 10.1158/1078-0432.CCR-11-2212. View

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee J, Lotvall J . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9(6):654-9. DOI: 10.1038/ncb1596. View

Xu J, Wu W, Zhang L, Dorset-Martin W, Morris M, Mitchell M . The role of microRNA-146a in the pathogenesis of the diabetic wound-healing impairment: correction with mesenchymal stem cell treatment. Diabetes. 2012; 61(11):2906-12. PMC: 3478555. DOI: 10.2337/db12-0145. View

Mishra P, Mishra P, Humeniuk R, Medina D, Alexe G, Mesirov J . Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008; 68(11):4331-9. PMC: 2725025. DOI: 10.1158/0008-5472.CAN-08-0943. View

10.

Noll J, Williams S, Tong C, Wang H, Quach J, Purton L . Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2013; 99(1):163-71. PMC: 4007935. DOI: 10.3324/haematol.2013.090977. View

11.

El-Saghir J, Nassar F, Tawil N, El-Sabban M . ATL-derived exosomes modulate mesenchymal stem cells: potential role in leukemia progression. Retrovirology. 2016; 13(1):73. PMC: 5070229. DOI: 10.1186/s12977-016-0307-4. View

12.

de Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K . Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Lett. 2016; 377(1):17-24. DOI: 10.1016/j.canlet.2016.04.024. View

13.

Yeung C, Co N, Tsuruga T, Yeung T, Kwan S, Leung C . Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016; 7:11150. PMC: 4820618. DOI: 10.1038/ncomms11150. View

14.

Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W . Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126(9):1106-17. PMC: 4560344. DOI: 10.1182/blood-2014-12-618025. View

15.

Kojima Y, Acar A, Eaton E, Mellody K, Scheel C, Ben-Porath I . Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci U S A. 2010; 107(46):20009-14. PMC: 2993333. DOI: 10.1073/pnas.1013805107. View

16.

Andrews S, Kabrah S, May J, Donaldson C, Morse H . Multiple myeloma: the bone marrow microenvironment and its relation to treatment. Br J Biomed Sci. 2013; 70(3):110-20. DOI: 10.1080/09674845.2013.11669945. View

17.

Bhaumik D, Scott G, Schokrpur S, Patil C, Campisi J, Benz C . Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27(42):5643-7. PMC: 2811234. DOI: 10.1038/onc.2008.171. View

18.

Abe M . [Cytokines and myeloma bone disease]. Clin Calcium. 2014; 24(6):871-8. DOI: CliCa1406871878. View

19.

Lugini L, Valtieri M, Federici C, Cecchetti S, Meschini S, Condello M . Exosomes from human colorectal cancer induce a tumor-like behavior in colonic mesenchymal stromal cells. Oncotarget. 2016; 7(31):50086-50098. PMC: 5226570. DOI: 10.18632/oncotarget.10574. View

20.

Wang J, Faict S, Maes K, de Bruyne E, Van Valckenborgh E, Schots R . Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget. 2016; 7(25):38927-38945. PMC: 5122441. DOI: 10.18632/oncotarget.7792. View